CYTK Buenos resultados, sport bios confiaba en ello. Llevo un 5%, máxima posición en condiciones normales, que desde que tengo la cartera reducida no es mucho pero algo le sacaremos.
Opinión de sheep (dueño del fondo Adar1 CM):
The ESC data could not be more bullish for $CYTK.
1. Their own MAPLE data (afi versus betablocker) is phenomenal
2. $BMY Mavacamten missed its co-primary endpoint in nHCM with p values of 0.056 and 0.066! It is not only possible, but likely that Aficamten will hit in nHCM next year, which would probably take $CYTK to $90+.
